Orla Cunningham

Orla Cunningham is the Chief Scientific Officer at Granular Therapeutics and Ultrahuman Eight, roles she has held since December 2020. In these positions, she is involved in developing novel single antibody therapies aimed at various medical conditions.146

Professional Background

Before joining Granular and Ultrahuman, Cunningham had an extensive career at Pfizer, where she served in several key roles, including Senior Director of the biotherapeutic discovery and optimization group. Her tenure at Pfizer lasted over a decade, during which she contributed significantly to pre-clinical programs and led multidisciplinary project teams.25

Cunningham began her career as a Postdoctoral Research Scientist at IFOM and then moved to Wyeth Research, where she established an antibody discovery and engineering group that later became part of Pfizer following its acquisition.2 She holds a PhD in Biochemistry from Trinity College Dublin.1

Contributions and Expertise

Cunningham has published and patented extensively in the field of therapeutic antibody engineering, showcasing her expertise in biochemistry and drug development. Her work has been recognized for advancing therapeutic options in various therapeutic areas.23